Skip navigation

24, 2016 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. ( IDRA ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform. In the presentation, entitled Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides, Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the region similar to that observed with siRNA. These excision products are different from those observed with earlier generations of antisense. This presentation also provided a demonstration of 3GAs specificity by showing that the incorporation of a mismatch at the region of excision led to the loss of gene-silencing activity. no dataBased on these studies, the company is also conducting studies to further the potential applications of 3GAs in targeting diseases caused by point mutations. Data from these studies is expected to be presented in the second half of 2016. This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. http://sandiegosunfire.com/evaclarkcity/2016/08/29/understanding-locating-aspects-for-retinal-detachment/In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. About Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html

If.veitis affects the iris, eye drops that dilate the pupil also may be prescribed so that the iris won’t move and cause pain. Tissue destruction is mediated by non-specific macrophage activation and the resulting cytosine cascades. 18 Serum TNF-α is significantly elevated in cases while IL-6 and IL-8 are present in significantly higher quantities in the aqueous humour in patients with both quiescent and active uveitis. 19 These are inflammatory markers that non-specific ally activate local macrophages causing tissue damage. The biliary body is a group of muscles and blood vessels that Phanges the shape of the lens so the eye can focus. Immunosuppressive agents can be taken via the mouth and are used to treat inflammation occurring at the back of the eyes. Does anything make your symptoms better or worse? A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation wow.Hon.ch. Seeking proper treatment for an autoimmune disease or infection can help to prevent uveitis. For some people, uveitis comes back again and again. Uveitis can also result from an autoimmune disorder . Uveitis. The vision and eye pressures will be measured, and the examination will involve careful observation of all parts of the eyes. If you take steroids for a long time, you may have side effects, like cataracts, stomach ulcers, bone thinning called osteoporosis, diabetes, and weight gain.

The.ost.ommon form of uveitis is anterior uveitis. It is often called iritis because it usually only affects the iris, the coloured part of the eye. A.D.A.M., Inc. is accredited by RAC, also known as the American Accreditation HealthCare Commission wow.uric.Borg. If the uveitis is caused by a body-wide infection, treatment may involve antibiotics and powerful anti-inflammatory medicines called corticosteroids. Drugs that reduce inflammation. Also called anterior uveitis, this is the most common type of uveitis. For more details on treatment plans, refer to treatment of uveitis . … more » Uveitis: Inflammation of the inner eye, which includes the iris, the biliary body that holds the lens of the eye; and the choroid plexus, a … more about Uveitis . She’ll give you an eye exam and ask you question about your symptoms, like: How is your vision? Corticosteroid eye drops are usually the first treatment recommended for uveitis affecting the front of the eye anterior uveitis that is not caused by an infection. Uveitis can cause permanent damage to the eyes and vision loss that cannot be reversed.

Leave a Reply

Your email address will not be published. Required fields are marked *